NCT00642928 - Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2009

Conditions

Excessive Daytime SleepinessParkinson's Disease

Interventions

DRUG

Placebo

1 capsule per day during 4 weeks

DRUG

BF 2.649 5 mg

one BF 2.649 capsule of 5 mg per day during 4 weeks

DRUG

BF 2.649 10 mg

One BF 2.649 capsule of 10 mg per day during 4 weeks

DRUG

BF 2.649 20 mg

One BF 2.649 capsule of 20 mg per day during 4 weeks

DRUG

BF 2.649 40 mg

One BF 2.649 capsule of 40 mg per day during 4 weeks

Trial Locations (1)

Pitié-Salpêtrière Hospital, Paris